Value Line Equity FundsMore Details

Mid Cap Focused
VLIFX - Investor Class

As Of 03/18/24

$34.02

NAV

$0.00

CHANGE

0.00%

CHANGE

VLMIX - Institutional Class

$34.29

NAV

$0.00

CHANGE

0.00%

CHANGE

Larger Companies Focused
VALLX - Investor Class

As Of 03/18/24

$32.35

NAV

$0.39

CHANGE

1.22%

CHANGE

VLLIX - Institutional Class

$33.00

NAV

$0.40

CHANGE

1.23%

CHANGE

Small Cap Opportunities
VLEOX - Investor Class

As Of 03/18/24

$54.46

NAV

$-0.22

CHANGE

-0.40%

CHANGE

VLEIX - Institutional Class

$56.10

NAV

$-0.23

CHANGE

-0.41%

CHANGE

Select Growth Fund
VALSX - Investor Class

As Of 03/18/24

$36.38

NAV

$0.14

CHANGE

0.39%

CHANGE

VILSX - Institutional Class

$36.87

NAV

$0.14

CHANGE

0.38%

CHANGE

Value Line Hybrid FundsMore Details

Asset Allocation
VLAAX - Investor Class

As Of 03/18/24

$41.88

NAV

$0.07

CHANGE

0.17%

CHANGE

VLAIX - Institutional Class

$41.98

NAV

$0.06

CHANGE

0.14%

CHANGE

Capital Appreciation
VALIX - Investor Class

As Of 03/18/24

$11.31

NAV

$0.01

CHANGE

0.09%

CHANGE

VLIIX - Institutional Class

$11.31

NAV

$0.01

CHANGE

0.09%

CHANGE

Per share net asset values are based on prices determined once daily as of the close of regular trading of the first session of the New York Stock Exchange (currently 4:00 p.m., New York time) on each day that the New York Stock Exchange is open for trading except on days on which no orders to purchase, sell, or redeem fund shares have been received. Prices are subject to change without notice.

You should carefully consider investment objectives, risks, charges and expenses of Value Line Funds before investing. This and other information can be found in the fund’s prospectus and summary prospectus, which can be obtained free of charge from your investment representative, by calling 800.243.2729, or by clicking on the applicable fund at www.vlfunds.com. Please read it carefully before you invest or send money. Value Line Funds are distributed by EULAV Securities LLC. Past performance is no guarantee of future results.